Jason Harris | Authors

June 04, 2022

According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.

May 27, 2022

After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.

April 25, 2022

Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.

April 24, 2022

In a phase 2 trial, rates of steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant were reduced.

April 12, 2022

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

April 10, 2022

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.